Data as of Mar 13
| -0.06 / -4.76%|
The 4 analysts offering 12-month price forecasts for ImmunoCellular Therapeutics Ltd have a median target of 4.75, with a high estimate of 12.00 and a low estimate of 1.25. The median estimate represents a +295.83% increase from the last price of 1.20.
The current consensus among 4 polled investment analysts is to Buy stock in ImmunoCellular Therapeutics Ltd. This rating has held steady since March, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.